The presented review with 74 references covers most of the methods described for the analysis of Rivaroxaban (RXB); the first and selective oral direct inhibitor of activated factor X in its pure forms, in different pharmaceutical dosage forms and in biological fluids. The review covers the period from 2005 till now.